A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations (Englisch)
- Neue Suche nach: Adès, Lionel
- Neue Suche nach: Duployez, Nicolas
- Neue Suche nach: Guerci‐Bresler, Agnes
- Neue Suche nach: Laribi, Kamel
- Neue Suche nach: Peterlin, Pierre
- Neue Suche nach: Vey, Norbert
- Neue Suche nach: Thepot, Sylvain
- Neue Suche nach: Wickenhauser, Stefan
- Neue Suche nach: Zerazhi, Hacene
- Neue Suche nach: Stamatoullas, Aspassia
- Neue Suche nach: Wattel, Eric
- Neue Suche nach: Recher, Christian
- Neue Suche nach: Toma, Andrea
- Neue Suche nach: Dimicoli‐Salazar, Sophie
- Neue Suche nach: Braun, Thorsten
- Neue Suche nach: Beyne‐Rauzy, Odile
- Neue Suche nach: Marolleau, Jean‐Pierre
- Neue Suche nach: Cheze, Stéphane
- Neue Suche nach: Park, Sophie
- Neue Suche nach: Cluzeau, Thomas
- Neue Suche nach: Nimubona, Stanislas
- Neue Suche nach: Bordessoule, Dominique
- Neue Suche nach: Benramdane, Riad
- Neue Suche nach: Quesnel, Bruno
- Neue Suche nach: Amé, Shanti
- Neue Suche nach: de Botton, Stéphane
- Neue Suche nach: Chermat, Fathia
- Neue Suche nach: Preudhomme, Claude
- Neue Suche nach: Chevret, Sylvie
- Neue Suche nach: Fenaux, Pierre
- Neue Suche nach: Adès, Lionel
- Neue Suche nach: Duployez, Nicolas
- Neue Suche nach: Guerci‐Bresler, Agnes
- Neue Suche nach: Laribi, Kamel
- Neue Suche nach: Peterlin, Pierre
- Neue Suche nach: Vey, Norbert
- Neue Suche nach: Thepot, Sylvain
- Neue Suche nach: Wickenhauser, Stefan
- Neue Suche nach: Zerazhi, Hacene
- Neue Suche nach: Stamatoullas, Aspassia
- Neue Suche nach: Wattel, Eric
- Neue Suche nach: Recher, Christian
- Neue Suche nach: Toma, Andrea
- Neue Suche nach: Dimicoli‐Salazar, Sophie
- Neue Suche nach: Braun, Thorsten
- Neue Suche nach: Beyne‐Rauzy, Odile
- Neue Suche nach: Marolleau, Jean‐Pierre
- Neue Suche nach: Cheze, Stéphane
- Neue Suche nach: Park, Sophie
- Neue Suche nach: Cluzeau, Thomas
- Neue Suche nach: Nimubona, Stanislas
- Neue Suche nach: Bordessoule, Dominique
- Neue Suche nach: Benramdane, Riad
- Neue Suche nach: Quesnel, Bruno
- Neue Suche nach: Amé, Shanti
- Neue Suche nach: de Botton, Stéphane
- Neue Suche nach: Chermat, Fathia
- Neue Suche nach: Preudhomme, Claude
- Neue Suche nach: Chevret, Sylvie
- Neue Suche nach: Fenaux, Pierre
In:
British Journal of Haematology
;
198
, 3
;
535-544
;
2022
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations
-
Beteiligte:Adès, Lionel ( Autor:in ) / Duployez, Nicolas ( Autor:in ) / Guerci‐Bresler, Agnes ( Autor:in ) / Laribi, Kamel ( Autor:in ) / Peterlin, Pierre ( Autor:in ) / Vey, Norbert ( Autor:in ) / Thepot, Sylvain ( Autor:in ) / Wickenhauser, Stefan ( Autor:in ) / Zerazhi, Hacene ( Autor:in ) / Stamatoullas, Aspassia ( Autor:in )
-
Erschienen in:British Journal of Haematology ; 198, 3 ; 535-544
-
Verlag:
-
Erscheinungsdatum:01.08.2022
-
Format / Umfang:10 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Schlagwörter:
-
Datenquelle:
Inhaltsverzeichnis – Band 198, Ausgabe 3
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 409
-
Issue Information| 2022
- 413
-
Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 regionPodvin, Benjamin / Guermouche, Hélène / Fournier, Elise / Berthon, Céline / Duployez, Nicolas / Roche‐Lestienne, Catherine et al. | 2022
- 414
-
Cerebral nocardiosis in ibrutinib‐treated chronic lymphocytic leukaemiaAlHaj Issa, Zahra / Altwijri, Abdulaziz / Alfayez, Mansour et al. | 2022
- 415
-
Enhancing our chances of picking a winner in higher‐risk myelodysplastic syndromesWei, Andrew H. / Seymour, John F. et al. | 2022
- 419
-
GOALs in relapsed DLBCLRösler, Wiebke / Zenz, Thorsten et al. | 2022
- 421
-
Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemiaValtis, Yannis K. / Place, Andrew E. / Silverman, Lewis B. / Vrooman, Lynda M. / DeAngelo, Daniel J. / Luskin, Marlise R. et al. | 2022
- 431
-
Bone health and glucocorticoid‐containing lymphoma therapy — a review of risk factors and preventative measuresEyre, Toby A. / Jensen, Paw / Booth, Stephen / El‐Galaly, Tarec Christoffer et al. | 2022
- 443
-
Thrombophilia testing: A British Society for Haematology guidelineArachchillage, Deepa J. / Mackillop, Lucy / Chandratheva, Arvind / Motawani, Jayashree / MacCallum, Peter / Laffan, Mike et al. | 2022
- 459
-
The use of next‐generation sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper *Roy, Noémi B. A. / Da Costa, Lydie / Russo, Roberta / Bianchi, Paola / Mañú‐Pereira, Maria del Mar / Fermo, Elisa / Andolfo, Immacolata / Clark, Barnaby / Proven, Melanie / Sanchez, Mayka et al. | 2022
- 478
-
Antibody responses to SARS‐CoV‐2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti‐cancer therapiesChan, Wei Yee / Zhu, Catherine / Sanchez, Emilie / Gupta, Rajeev / Fielding, Adele K. / Khwaja, Asim / Payne, Elspeth M. / O'Nions, Jenny et al. | 2022
- 482
-
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialHess, Georg / Hüttmann, Andreas / Witzens‐Harig, Mathias / Dreyling, Martin H. / Keller, Ulrich / Marks, Reinhard / Ernst, Thomas / Pott, Christiane / Viardot, Andreas / Frontzek, Fabian et al. | 2022
- 492
-
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experienceKuhnl, Andrea / Roddie, Claire / Kirkwood, Amy A. / Tholouli, Eleni / Menne, Tobias / Patel, Amit / Besley, Caroline / Chaganti, Sridhar / Sanderson, Robin / O'Reilly, Maeve et al. | 2022
- 503
-
Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myelomaCho, Hyunsoo / Shin, Saeam / Chung, Haerim / Jang, Ji Eun / Kim, Yu Ri / Cheong, June‐Won / Min, Yoo Hong / Lee, Seung‐Tae / Choi, Jong Rak / Kim, Jin Seok et al. | 2022
- 515
-
Minimal residual disease and imaging‐guided consolidation strategies in newly diagnosed and relapsed refractory multiple myelomaBöckle, David / Tabares, Paula / Zhou, Xiang / Schimanski, Sven / Steinhardt, Maximilian J. / Bittrich, Max / Seebacher, Elena / Ulbrich, Maria / Wilnit, Amy / Metz, Corona et al. | 2022
- 523
-
VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome‐negative B‐precursor acute lymphoblastic leukaemia in first relapseHeraudet, Luc / Galtier, Jean / Favre, Simon / Peyraud, Florent / Cazaubiel, Titouan / Leroy, Harmony / Mottal, Nathan / Gros, François‐Xavier / Forcade, Edouard / Clément, Laurence et al. | 2022
- 528
-
A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trialRussell, Nigel H. / Hills, Robert K. / Kjeldsen, Lars / Clark, Richard E. / Ali, Sahra / Cahalin, Paul / Thomas, Ian F. / Burnett, Alan K. et al. | 2022
- 535
-
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutationsAdès, Lionel / Duployez, Nicolas / Guerci‐Bresler, Agnes / Laribi, Kamel / Peterlin, Pierre / Vey, Norbert / Thepot, Sylvain / Wickenhauser, Stefan / Zerazhi, Hacene / Stamatoullas, Aspassia et al. | 2022
- 545
-
Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population‐based studySánchez‐Vizcaíno, Fernando / Tamayo, Carmen / Ramos, Fernando / Láinez‐González, Daniel / Serrano‐López, Juana / Barba, Raquel / Martin, Maria Dolores / Llamas, Pilar / Alonso‐Dominguez, Juan Manuel et al. | 2022
- 556
-
T‐helper cell regulation of CD45 phosphatase activity by galectin‐1 and CD43 governs chronic lymphocytic leukaemia proliferationImbery, John F. / Heinzelbecker, Julia / Jebsen, Jenny K. / McGowan, Marc / Myklebust, Camilla / Bottini, Nunzio / Stanford, Stephanie M. / Skånland, Sigrid S. / Tveita, Anders / Tjønnfjord, Geir E. et al. | 2022
- 574
-
Retention of functional mitochondria in mature red blood cells from patients with sickle cell diseaseMoriconi, Chiara / Dzieciatkowska, Monika / Roy, Micaela / D'Alessandro, Angelo / Roingeard, Philippe / Lee, June Young / Gibb, David R. / Tredicine, Maria / McGill, Marlon A. / Qiu, Annie et al. | 2022
- 587
-
Haematological variables and risk of future venous thromboembolism in the British Regional Heart Study on men. Combined D‐dimer and APTT as a predictive test for thromboembolism?Wannamethee, S. Goya / Papacosta, Olia / Lennon, Lucy / Whincup, Peter H. / Rumley, Ann / Lowe, Gordon D. O. et al. | 2022
- 595
-
Characteristics, management and outcome of acquired amegakaryocytic thrombocytopeniaRoeser, Anais / Moulis, Guillaume / Ebbo, Mikael / Terriou, Louis / Poullot, Elsa / Lioger, Bertrand / Chilles, Marie / Labussière‐Wallet, Helene / Mausservey, Christelle / Pha, Micheline et al. | 2022
- 600
-
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment‐free remissionLu, Liu / Kok, Chung Hoow / Dang, Phuong / Branford, Susan / Saunders, Verity A. / Shanmuganathan, Naranie / Ross, David M. / Hughes, Timothy P. / Yeung, David T. O. et al. | 2022
- 604
-
Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survivalWang, Xiaoqiong / Tang, Guilin / Hu, Zhihong / Fang, Hong / Wang, Wei / Tang, Zhenya / Toruner, Gokce A. / Zhou, Ting / DiNardo, Courtney D. / Garcia‐Manero, Guillermo et al. | 2022
- 609
-
Corrigendum| 2022
- 610
-
Erratum| 2022
- e35
-
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemiaJamy, Omer / Lin, Karen / Worth, Sarah / Bachiashvili, Kimo / Rangaraju, Sravanti / Vachhani, Pankit / Bhatia, Ravi et al. | 2022
- e38
-
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myelomaKawano, Yawara / Hata, Hiroyuki / Takashio, Seiji / Tsujita, Kenichi / Ueda, Mitsuharu / Matsuoka, Masao et al. | 2022
- e42
-
Limited value of the D‐dimer based YEARS algorithm to rule out pulmonary embolism in sickle cell disease and sickle cell traitGaartman, Aafke E. / Strijdhorst, Anniek / van Es, Nick / Tang, Man Wai / Heijmans, Jarom / Biemond, Bart J. / Nur, Erfan / SCORE consortium et al. | 2022
- e46
-
Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER studyNishimura, Jun‐ichi / Usuki, Kensuke / Ramos, Julia / Ichikawa, Satoshi / Buri, Muriel / Kiialainen, Anna / Sostelly, Alexandre / Peffault de Latour, Régis / Paz‐Priel, Ido / Röth, Alexander et al. | 2022